Dare Bioscience Inc (OQ:DARE)

Business Focus: Biotechnology & Medical Research

May 07, 2024 08:00 am ET
Daré Bioscience to Host First Quarter 2024 Financial Results and Company Update Conference Call and Webcast on May 14, 2024
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Tuesday, May 14, 2024, to review its financial results for the quarter...
May 02, 2024 08:00 am ET
Daré Bioscience Selected as a Member of ARPA-H Investor Catalyst Hub Spoke Network
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced it was selected as a spoke for the Investor Catalyst Hub, a regional hub of ARPANET-H, a nationwide health innovation network launched by the Advanced...
Apr 30, 2024 07:30 am ET
Daré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women’s Health Product Candidates through Key Catalysts
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced it has closed a royalty monetization transaction with XOMA (US) LLC. Daré received $22 million in gross proceeds at close and, following a pre-specified...
Apr 23, 2024 08:00 am ET
Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced it will receive a payment of $1 million as the latest installment under a grant agreement to advance the development of Daré’s investigational...
Apr 11, 2024 08:00 am ET
Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravagi
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced the publication of data from the postcoital test clinical study of Ovaprene in two original research articles in the journal Contraception. Publication...
Mar 28, 2024 08:00 am ET
Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reported financial results for the year ended December 31, 2023 and provided a company update. “We are pleased with the incredible progress we made in 2023 with our...
Mar 21, 2024 08:00 am ET
Daré Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, March 28, 2024, to review its financial results for the year...
Feb 22, 2024 08:00 am ET
Daré Bioscience to Present at the International Society for the Study of Women’s Sexual Health (ISSWSH) Annual Meeting
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that additional data from the exploratory Phase 2b RESPOND clinical study of Sildenafil Cream, 3.6% (Sildenafil Cream) in women with female sexual arousal...
Jan 31, 2024 08:00 am ET
Daré Bioscience Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, and its collaborator Strategic Science & Technologies, LLC (SST), a Cambridge, MA based novel topical drug delivery company, today announced the successful completion of...
Jan 26, 2024 04:30 pm ET
Daré Bioscience Announces Executive Team and Board of Directors Changes
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced changes in company management which includes the retirement of Chief Financial Officer, Lisa Walters-Hoffert, and the resignation of Chief Commercial...
Jan 17, 2024 08:00 am ET
Daré Bioscience Announces Grant to Support Biotherapeutic Product Development
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced it has received a grant from the Bill & Melinda Gates Foundation (the foundation) of $750,000 to fund activities related to bacteria-based live...
Jan 04, 2024 08:00 am ET
Daré Bioscience’s DARE-LARC1 Platform Technology Achieves Proof-of-Concept Device that has Transformative Potential for Women’s Health as well as in Treating a Broad Range of Diseases
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it has achieved technological proof of concept for DARE-LARC1 and the underlying innovative drug delivery platform designed to store and precisely...
Dec 26, 2023 08:00 am ET
Daré Bioscience Secures $12 million in Royalty-backed Investment Structure
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced it has entered into a royalty-backed financing agreement that provides Daré with $5 million at closing and up to an additional $7 million through three...
Dec 20, 2023 08:00 am ET
Daré Bioscience Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the DARE-PDM1 Phase 1 Clinical Study
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced positive topline results from the Phase 1 study evaluating the pharmacokinetics (PK), safety, and exploratory efficacy of DARE-PDM1. DARE-PDM1 is an...
Dec 13, 2023 08:00 am ET
Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to Support DARE-PTB1
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it received a Notice of Award of a grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), a division...
Dec 07, 2023 08:00 am ET
Daré Bioscience Announces FDA Clearance of Investigational New Drug (IND) Application for DARE-VVA1, a Novel Intravaginal Formulation of Tamoxifen for Moderate to Severe Dyspareunia, a Symptom of Vulv
Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for DARE-VVA1, a novel intravaginal proprietary...
Dec 04, 2023 08:00 am ET
Daré Bioscience Announces Commencement of Phase 3 Study of Ovaprene®, an Investigational Hormone-Free Monthly Intravaginal Contraceptive
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced commencement of the Company’s pivotal Phase 3 clinical study of Ovaprene, an investigational hormone-free monthly intravaginal contraceptive. The...
Nov 20, 2023 08:00 am ET
Daré Bioscience and Premier Research Extend Strategic Partnership to Accelerate the Clinical Development of Daré’s Novel Women’s Health Programs
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, and Premier Research International, LLC, a global clinical research, product development, and consulting company, today announced that the companies extended their...
Nov 13, 2023 08:00 am ET
Daré Bioscience to Present at the Sexual Medicine Society of North America (SMSNA) 24th Annual Fall Scientific Meeting
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, and its collaborator Strategic Science & Technologies, LLC (SST), a Cambridge, MA based novel topical drug delivery company, today announced that an overview of the...
Nov 09, 2023 08:00 am ET
Daré Bioscience Reports Third Quarter 2023 Financial Results and Provides Company Update
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reported financial results for the quarter ended September 30, 2023 and provided a company update. “We are pleased with the incredible progress we have made since...
Nov 06, 2023 08:00 am ET
Daré Bioscience to Participate in Three November Conferences
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that the company’s President and CEO, Sabrina Martucci Johnson, and Medical Advisor Andrew T. Goldstein, MD, will participate in the following conferences...
Nov 02, 2023 08:00 am ET
Daré Bioscience to Host Third Quarter 2023 Financial Results and Company Update Conference Call and Webcast on November 9, 2023
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, November 9, 2023, to review its financial results for the...
Nov 01, 2023 08:00 am ET
Daré Bioscience Announces Additional Positive Data from Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women and Proposed Endpoints and Patient Population for Phase 3 Program
Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, and its collaborator Strategic Science & Technologies, LLC (SST), a Cambridge, MA based novel topical drug delivery company, today announced additional positive findings...
Oct 16, 2023 08:00 am ET
Daré Bioscience Announces Achievement of First Commercial Milestone Under License Agreement for XACIATO™ (Clindamycin Phosphate) Vaginal Gel, 2%, FDA-Approved Treatment for Bacterial Vaginosis in Fema
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced the first shipment of XACIATOTM [pronounced zah-she-AH-toe] (clindamycin phosphate) vaginal gel, 2% in connection with the first commercial sale of the...
Sep 21, 2023 08:00 am ET
Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced it will receive a payment of approximately $4.5 million as the latest installment under a grant agreement to advance the development of Daré’s...
Sep 20, 2023 08:00 am ET
Daré Bioscience to Present at The Menopause Society 2023 Annual Meeting
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Dr. Andrew Goldstein, Daré Medical Advisor, will present at the 2023 Annual Meeting of The Menopause Society (formerly known as The North American...
Sep 06, 2023 08:00 am ET
Daré Bioscience to Participate in Upcoming Investor Conferences
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, the company’s President and CEO, will participate in the following investor conferences in September 2023: Event:H.C....
Sep 05, 2023 08:00 am ET
Daré Bioscience Completes Previously Announced Equity Financing
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced the completion of its registered direct offering of common stock and warrants to purchase common stock priced at-the-market under Nasdaq rules with an...
Aug 30, 2023 08:00 am ET
Daré Bioscience Announces $7.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it has entered into a definitive agreement with an institutional investor and an investor affiliated with the licensor of one of the company’s early...
Aug 10, 2023 08:00 am ET
Daré Bioscience Reports Second Quarter 2023 Financial Results and Provides a Company Update
preparations for end-of-Phase 2 meeting with FDADARE-PDM1 (primary dysmenorrhea) – Phase 1 Clinical Study Topline DataMenopause programs: IND related activities for DARE-HRT1 (vasomotor symptoms of menopause) and DARE-VVA1 (vulvovaginal atrophy, a...
Aug 09, 2023 08:00 am ET
Daré Bioscience Announces Publication in The Journal of The North American Menopause Society of Positive Efficacy Findings for the Treatment of Menopausal Symptoms from a Phase 1/2 Clinical Trial of D
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced the publication of positive preliminary efficacy results from its Phase 1/2 clinical study of DARE-HRT1 in healthy postmenopausal women. DARE-HRT1, an...
Aug 03, 2023 08:00 am ET
Daré Bioscience to Host Second Quarter 2023 Financial Results and Company Update Conference Call and Webcast on August 10, 2023
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, August 10, 2023, to review its financial results for the...
Jul 31, 2023 08:00 am ET
Daré Bioscience Announces Grant Award Supporting Development of Potential New Therapeutic Intervention for the Prevention of Idiopathic Preterm Birth
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced it was awarded a grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) of the National Institutes of...
Jul 11, 2023 05:30 pm ET
Daré Bioscience to Present at the 9th Annual International Symposium of Drug Delivery Systems
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that the company’s Chief Scientific Officer, David Friend, Ph.D., will present during the Novel Drug Delivery Technologies, Systems and Devices section of...
Jul 11, 2023 08:00 am ET
Daré Bioscience Announces Additional Positive Data from Exploratory Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, and its collaborator Strategic Science & Technologies, LLC (SST), a Cambridge, MA based novel topical drug delivery company, today announced additional positive data from...
Jul 06, 2023 08:00 am ET
Daré Bioscience Announces Upcoming Webinar to Review Additional Data from Exploratory Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a virtual Key Opinion Leader (KOL) webinar on Tuesday, July 11, 2023, at 4:30 p.m. EDT to review additional data from its exploratory...
Jul 05, 2023 08:00 am ET
Daré Bioscience Provides Update on Activities to Support Commercial Launch of XACIATO™ (clindamycin phosphate) vaginal gel, 2%, FDA-Approved Treatment for Females 12 and Older with Bacterial Vaginosis
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reaffirmed its commitment to the commercial launch of XACIATO [zah-she-AH-toe] (clindamycin phosphate) vaginal gel, 2% with collaborator Organon (NYSE: OGN), and...
Jun 21, 2023 08:00 am ET
Daré Bioscience Announces Publication in Menopause: The Journal of The North American Menopause Society of Data from Phase 1/2 Open-Label Safety and Pharmacokinetics Study of DARE-HRT1 in Healthy Post
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced the publication in Menopause: The Journal of The North American Menopause Society of data from a Phase 1/2 clinical trial that evaluated the safety and...
Jun 14, 2023 08:00 am ET
Daré Bioscience to Present at the Maxim Group Virtual Healthcare Conference
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, the company’s President and CEO, will present at the Healthcare Virtual Conference presented by Maxim Group LLC and hosted...
Jun 09, 2023 08:00 am ET
Daré Bioscience Announces Publication of Phase 1/2 Pharmacokinetic, Safety and Pharmacodynamic Data for DARE-VVA1 - a Potential New Hormone-Free Treatment for Vulvovaginal Atrophy - in Climacteric, th
Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced the publication of results of its Phase 1/2 clinical study of DARE-VVA1, a proprietary, investigational formulation of tamoxifen for intravaginal...
Jun 05, 2023 08:00 am ET
Daré Bioscience Announces Positive Topline Data from the Exploratory Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, and its collaborator Strategic Science & Technologies, LLC (SST), a Cambridge, MA based novel topical drug delivery company, today announced positive topline data from the...
Jun 01, 2023 08:00 am ET
Daré Bioscience to Participate in Two Upcoming Conferences: 2023 BIO International Convention and the Longwood Healthcare Leaders Spring 2023 MIT Conference
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, the company’s President and CEO, will participate in two conferences during the week of June 5th: BIO International...
May 31, 2023 08:00 am ET
Daré Bioscience Announces Availability of Publication on the Patient-Centered Concept Elicitation Study for Female Sexual Arousal Disorder in The Journal of Sexual Medicine
Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced the publication of results of the patient-centered study designed to elucidate the commonly reported symptoms, including severity of symptoms, associated...
May 11, 2023 08:00 am ET
Daré Bioscience Reports First Quarter 2023 Financial Results and Provides a Company Update
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reported financial results for the quarter ended March 31, 2023 and provided a company update. “Our focused efforts to deliver differentiated innovation in...
May 04, 2023 08:00 am ET
Daré Bioscience to Host First Quarter 2023 Financial Results and Company Update Conference Call and Webcast on May 11, 2023
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, May 11, 2023, to review its financial results for the quarter...
Apr 20, 2023 08:00 am ET
Daré Bioscience Announces Initiation of Subject Enrollment in a Phase 1 Thermography Study to Support Pharmacodynamic and Pharmacokinetic Characterization of Sildenafil Cream, 3.6%
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, and Strategic Science & Technologies, LLC (SST), a Cambridge, MA based novel topical drug delivery company, today announced initiation of screening and enrollment for a...
Apr 19, 2023 08:00 am ET
David Friend, Ph.D., Chief Scientific Officer of Daré Bioscience, Inc., to Present at the Global Pharma & Drug Delivery Summit 2023 to be held April 24-26, 2023 in Frankfurt, Germany
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that the company’s Chief Scientific Officer, David Friend, Ph.D., will be presenting in the Keynote Forum of the Global Pharma & Drug Delivery Summit 2023...
Apr 18, 2023 08:00 am ET
Daré Bioscience Announces Publication of Positive Safety and Acceptability Data from Phase 1 Clinical Trial that Support the Potential of DARE-HRT1 Intravaginal Ring as a New Menopausal Hormone Therap
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Climacteric, the official journal of the International Menopause Society, published safety and acceptability results from a Phase 1 clinical trial of...
Apr 17, 2023 08:00 am ET
Daré Bioscience to Participate in Xpectives.Health SUMMIT Innovations in Women’s Health Business Conference
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, the company’s President and CEO, will participate in a panel discussion at the Innovations in Women’s Health Business...
Mar 30, 2023 08:00 am ET
Daré Bioscience Reports Full Year 2022 Financial Results and Provides a Company Update
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reported financial results for the year ended December 31, 2022 and provided a company update. “Daré announced a number of positive developments related to our...
Mar 23, 2023 08:00 am ET
Daré Bioscience to Host Full-year 2022 Financial Results and Company Update Conference Call and Webcast on March 30, 2023
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, March 30, 2023, to review its financial results for the year...
Mar 01, 2023 08:00 am ET
Daré Bioscience to Present at the 35th Annual Roth Conference
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, the company’s President and CEO, will present at the 35th Annual Roth Conference, being held March 12-14, 2023 in Laguna...
Feb 22, 2023 08:00 am ET
Daré Bioscience Announces Start of a Phase 1 Study for its Potential First-in-Category Treatment for Primary Dysmenorrhea, DARE-PDM1
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced the start of a Phase 1 study evaluating its development program targeted at treating primary dysmenorrhea by delivering the active pharmaceutical...
Feb 01, 2023 08:00 am ET
Daré Bioscience to Participate in Three February Conferences
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, the company’s President and CEO, will participate in the following February conferences: 2023 BIO CEO & Investor...
Jan 26, 2023 08:00 am ET
Daré Bioscience Announces Publication in Menopause: The Journal of The North American Menopause Society of Data from Phase 1 Trial of DARE-HRT1 that Support the Potential of DARE-HRT1 as an Effective
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced the publication of data from a Phase 1 trial evaluating the pharmacokinetics of DARE-HRT1, an investigational intravaginal ring (IVR) designed to deliver...
Jan 09, 2023 08:00 am ET
Daré Bioscience Announces Positive Pharmacokinetic (PK) Results from the DARE-HRT1 Phase 1 / 2 Study that Support the Potential of DARE-HRT1 as an Effective Hormone Therapy for both Vasomotor and Vagi
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced topline PK results from its Phase 1 / 2 clinical trial of DARE-HRT1 that support the potential of DARE-HRT1 as an effective hormone therapy (HT) based on...
Dec 12, 2022 08:00 am ET
Daré Bioscience Announces New Development Program, DARE-PDM1, as a Potential First-in-Category Treatment for Primary Dysmenorrhea
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced a new development program targeted at treating primary dysmenorrhea by delivering the active pharmaceutical ingredient diclofenac, a nonsteroidal...
Nov 15, 2022 08:00 am ET
Daré Bioscience Announces Grant to Develop Novel Hydrogel Formulation for Delivery of Live Biotherapeutics to Support Vaginal Health
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced it has received a grant from the Bill & Melinda Gates Foundation (the foundation) of $584,986 to support activities related to development of a vaginal...
Nov 14, 2022 08:00 am ET
Daré Bioscience Announces Positive Topline Results from DARE-VVA1 Phase 1/2 Clinical Study
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced topline data from its Phase 1/2 clinical study of DARE-VVA1, a novel intravaginal proprietary formulation of tamoxifen being developed for the treatment of...
Nov 10, 2022 05:45 am ET
Daré Bioscience Reports Third Quarter 2022 Financial Results and Provides a Company Update
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reported financial results for the quarter ended September 30, 2022 and provided a company update. “During the third quarter, we received $18.0 million in...
Nov 08, 2022 08:00 am ET
Daré Bioscience to Present at the Stifel 2022 Healthcare Conference
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, the company’s President and CEO, will present at the Stifel 2022 Healthcare Conference, being held November 15-16, 2022 in...
Nov 03, 2022 08:00 am ET
Daré Bioscience to Host Third Quarter 2022 Financial Results and Company Update Conference Call and Webcast on November 10, 2022
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, November 10, 2022, to review its financial results for the...
Nov 01, 2022 08:00 am ET
Daré Bioscience Announces Subject Screening for Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder Complete
Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, and Strategic Science & Technologies, LLC (SST), a Cambridge, MA based novel topical drug delivery company, today announced that subject screening for the exploratory Phase...
Oct 17, 2022 08:00 am ET
Daré Bioscience Announces Positive Efficacy Results from the DARE-HRT1 Phase 1 / 2 Study
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced positive topline efficacy results from its Phase 1 / 2 clinical trial of DARE-HRT1. DARE-HRT1 is a novel, investigational intravaginal ring (IVR) designed...
Oct 10, 2022 08:00 am ET
Daré Bioscience Announces IDE Approval for a Single Arm, Open-Label Pivotal Contraceptive Efficacy Study of Ovaprene®, an Investigational Hormone-Free Monthly Intravaginal Contraceptive
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that the U.S. Food & Drug Administration (FDA) approved an Investigational Device Exemption (IDE) application allowing Daré to conduct a single arm,...
Sep 15, 2022 08:00 am ET
Daré Bioscience to Participate in Two Upcoming Conferences
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, the company’s President and CEO, will participate in two upcoming conferences. Informa Connect Women’s Healthcare Access &...
Sep 06, 2022 08:00 am ET
Daré Bioscience to Participate in H.C. Wainwright 24th Annual Global Investment Conference
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, the company’s President and CEO, will participate in a fireside chat during the H.C. Wainwright 24th Annual Global...
Aug 29, 2022 08:00 am ET
Daré Bioscience Announces Interim Analysis of Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder
Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, and Strategic Science & Technologies, LLC (SST), a Cambridge, MA based novel topical drug delivery company, today announced that, based on the results of an interim...
Aug 24, 2022 08:00 am ET
Daré Bioscience, Inc. Announces Global Licensing Rights to the Novel Antimicrobial Glycerol Monolaurate for Vaginal Health
Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced that it has entered into a license agreement with Hennepin Life Sciences LLC under which Daré acquired the exclusive global rights to develop and...
Aug 09, 2022 08:00 am ET
Daré Bioscience Reports Second Quarter 2022 Financial Results and Provides a Company Update
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reported financial results for the quarter ended June 30, 2022 and provided a company update. “In the second quarter, we closed our global license agreement with...
Aug 02, 2022 08:00 am ET
Daré Bioscience to Host Second Quarter 2022 Financial Results and Company Update Conference Call and Webcast on August 9, 2022
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Tuesday, August 9, 2022, to review its financial results for the quarter...
Jul 07, 2022 08:00 am ET
Daré Bioscience to Participate in Maxim Group Women’s Health Panel
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, its President and CEO, will be participating in a virtual panel discussion presented by Maxim Group LLC and hosted by...
Jun 30, 2022 08:00 am ET
Daré Bioscience Announces Closing of Global License Agreement with Organon to Commercialize XACIATO™ (clindamycin phosphate vaginal gel, 2%), FDA-Approved Treatment for Females 12 and Older with Bacte
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that the exclusive license agreement entered into on March 31, 2022 with Organon (NYSE: OGN), a global women’s healthcare company, has become fully...
Jun 24, 2022 08:00 am ET
Daré Bioscience Announces Partial Adjournment of Annual Meeting of Stockholders to July 14, 2022
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced partial adjournment of its 2022 Annual Meeting of Stockholders (the “Annual Meeting”) and voting results on all but one of the proposals. All of the...
Jun 06, 2022 08:00 am ET
Daré Bioscience to Participate in the 2022 BIO International Convention
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, the company’s President and CEO, will participate in a panel discussion and deliver a company presentation during the 2022...
May 16, 2022 08:00 am ET
Daré Bioscience to Participate in H.C. Wainwright Global Investment Conference
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, the company’s President and CEO, will participate in a virtual fireside chat during the H.C. Wainwright Global Investment...
May 12, 2022 06:00 am ET
Daré Bioscience Reports First Quarter 2022 Financial Results and Provides a Company Update
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reported financial results for the quarter ended March 31, 2022 and provided a company update. “Our global license agreement with Organon to commercialize XACIATO,...
May 11, 2022 08:00 am ET
Daré Bioscience Announces NIH Grant Award
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced a Notice of Award of a grant from the Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) of the National Institutes of...
May 05, 2022 08:00 am ET
Daré Bioscience to Host First Quarter 2022 Financial Results and Company Update Conference Call and Webcast on May 12, 2022
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, May 12, 2022, to review its financial results for the quarter...
Apr 14, 2022 08:00 am ET
Daré Bioscience to Participate in Upcoming Conference
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, the company’s President and CEO, will participate in a panel discussion at the Innovations in Women’s Health Business...
Apr 12, 2022 08:00 am ET
Daré Bioscience Initiates Phase 1/2 Clinical Study of DARE-HRT1
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced the initiation of a Phase 1/2 clinical study of DARE-HRT1. DARE-HRT1 is a novel intravaginal ring (IVR) designed to deliver bio-identical 17β-estradiol...
Mar 31, 2022 08:00 am ET
Daré Bioscience Reports Full-Year 2021 Financial Results and Provides a Company Update
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reported financial results for the year ended December 31, 2021 and provided a company update. “We made significant progress across the portfolio during 2021 and...
Mar 31, 2022 07:00 am ET
Organon Enters into Global License Agreement to Commercialize Daré Bioscience’s XACIATO™ (clindamycin phosphate vaginal gel, 2%), FDA-Approved Treatment for Females 12 and Older with Bacterial Vaginos
Organon (NYSE: OGN), a global women’s healthcare company, and Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced they have entered into an agreement whereby Organon will license global rights to XACIATO (clindamycin phosphate vaginal gel, 2%). XACIATO is an FDA-approved medication for the treatment of bacterial vaginosis (BV) in females 12 years of age and older. XACIATO received both Qualified Infectious Disease Product (QIDP) and Fast Track designations from the FDA for the treatment of bacterial vaginosis.
Mar 24, 2022 08:00 am ET
Daré Bioscience to Host Full-year 2021 Financial Results and Company Update Conference Call and Webcast on March 31, 2022
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, March 31, 2022, to review its financial results for the year...
Mar 22, 2022 08:00 am ET
Daré Bioscience to Present at the Maxim 2022 Virtual Growth Conference
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, its President and CEO, will participate in the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by...
Mar 02, 2022 08:00 am ET
Daré Bioscience to Participate in Upcoming Conferences
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that members of its management team will participate in the following conferences: Cowen 42nd Annual Health Care Conference March 7-9, 2022,...
Feb 07, 2022 08:00 am ET
Daré Bioscience to Participate in Upcoming Conferences
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, its President and Chief Executive Officer, will participate in the following upcoming conferences: 2022 BIO CEO & Investor...
Jan 04, 2022 08:00 am ET
Daré Bioscience to Participate in H.C. Wainwright BIOCONNECT 2022 Conference
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, its President and Chief Executive Officer, will deliver a company presentation at the H.C. Wainwright BIOCONNECT 2022...
Dec 09, 2021 09:45 am ET
Thinking about buying stock in American Virtual Cloud Technologies, Nokia, Phunware, SentinelOne, or Dare Bioscience?
NEW YORK, Dec. 9, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AVCT, NOK, PHUN, S, and DARE.
Dec 08, 2021 07:31 am ET
Thinking about buying stock in Dare Bioscience, RLX Technology, Pagerduty, Barnes & Noble Education, or Waitr Holdings?
NEW YORK, Dec. 8, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DARE, RLX, PD, BNED, and WTRH.
Dec 07, 2021 04:15 pm ET
Daré Announces FDA Approval of XACIATO™ (clindamycin phosphate) Vaginal Gel as a Treatment for Bacterial Vaginosis
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that the U.S. Food and Drug Administration (FDA) approved XACIATO [zah-she-AH-toe] (clindamycin phosphate vaginal gel, 2%) (formerly known as DARE-BV1) for...
Dec 03, 2021 08:31 am ET
Thinking about buying stock in Xenon Pharmaceuticals, Maxeon Solar Technologies, Aurora Mobile, XpresSpa Group, or Dare Bioscience?
NEW YORK, Dec. 3, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for XENE, MAXN, JG, XSPA, and DARE.
Nov 10, 2021 08:00 am ET
Daré Bioscience Reports Third Quarter 2021 Financial Results and Provides a Company Update
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reported financial results for the quarter ended September 30, 2021 and provided a company update. “We’ve continued to make significant progress on several key...
Nov 09, 2021 08:00 am ET
Daré Bioscience to Present at the Stifel 2021 Virtual Healthcare Conference
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, its President and Chief Executive Officer, will present at the Stifel 2021 Virtual Healthcare Conference being held November...
Nov 03, 2021 08:00 am ET
Daré Bioscience to Host Third Quarter 2021 Financial Results and Company Update Conference Call and Webcast on November 10, 2021
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Wednesday, November 10, 2021, to review its financial results for the...
Oct 06, 2021 08:51 am ET
Daré Bioscience to Participate in Panel Discussion at DTC Perspectives’ Xpectives.Health Summit, October 12-14, 2021
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced its participation in DTC Perspectives’ Xpectives.Health Summit being held in Boston, MA from October 12 – 14, 2021, at The Westin Copley Place. “I’m...
Sep 27, 2021 08:00 am ET
Daré Bioscience Announces NIH Grant Award to Support Development of DARE-LARC1
Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced a Notice of Award of a grant from the Eunice Kennedy Shriver National Institute Of Child Health & Human Development (NICHD), a division of the National...
Sep 23, 2021 08:00 am ET
Daré Bioscience Initiates Phase 1/2 Clinical Study of DARE-VVA1, Intravaginal Tamoxifen for the Treatment of Vulvar and Vaginal Atrophy
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced the initiation of a Phase 1/2 clinical study of DARE-VVA1, a novel intravaginal tamoxifen product being developed for the treatment of moderate to severe...
Sep 22, 2021 08:00 am ET
Daré Bioscience to Present at the 2021 Cantor Virtual Global Healthcare Conference
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, its President and Chief Executive Officer, will present at the Virtual Global Healthcare Conference being hosted by the...
Sep 08, 2021 08:00 am ET
Daré Bioscience to Participate in H.C. Wainwright 23rd Annual Global Investment Conference
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, its President and Chief Executive Officer, will deliver a company presentation at the H.C. Wainwright 23rd Annual Global...
Sep 07, 2021 08:00 am ET
Daré Bioscience to Participate in Panel Discussion at Women’s Health Innovation Summit
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced its participation in the Women’s Health Case Study: Optimizing Study Enrollment During the COVID-19 Pandemic panel at the Women’s Innovation Summit being...
Sep 01, 2021 08:00 am ET
Daré Bioscience to Present at the 13th European Congress on Menopause and Andropause
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that David Friend, PhD, the company’s Chief Scientific Officer, will present data from the company’s Phase 1 pharmacokinetic and safety study of DARE-HRT1...
Aug 12, 2021 08:00 am ET
Daré Bioscience Reports Second Quarter 2021 Financial Results and Provides a Company Update
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reported financial results for the quarter ended June 30, 2021 and provided a company update. “This has been, and continues to be, an incredibly productive year for...
Aug 09, 2021 09:31 am ET
Thinking about buying stock in Golden Nugget Online Gaming, Dare Bioscience, Liminal BioSciences, Windtree Therapeutics, or Daseke Inc?
NEW YORK, Aug. 9, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GNOG, DARE, LMNL, WINT, and DSKE.
Aug 09, 2021 08:00 am ET
Daré Bioscience Announces FDA Acceptance and Priority Review of New Drug Application for DARE-BV1 for the Treatment of Bacterial Vaginosis
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that the U.S. Food and Drug Administration (FDA) accepted for filing the company’s New Drug Application (NDA) for DARE-BV1 for the treatment of bacterial...
Aug 05, 2021 08:00 am ET
Daré Bioscience to Host Second Quarter 2021 Financial Results and Company Update Conference Call and Webcast on August 12, 2021
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, August 12, 2021, to review its financial results for the...
Jul 26, 2021 08:00 am ET
Daré Bioscience to Present at the 2021 Controlled Release Society Virtual Annual Meeting to be held July 25-29, 2021
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that David Friend, PhD, the company’s Chief Scientific Officer, will present data from preclinical and clinical studies related to DARE-BV1 at the 2021...
Jul 16, 2021 11:15 am ET
Thinking about buying stock in Verb Technology, Ericsson, Dare Bioscience, ContextLogic, or Climate Chang Cris Real Impct I Acq Corp?
NEW YORK, July 16, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VERB, ERIC, DARE, WISH, and EVGO.
Jul 12, 2021 09:31 am ET
Thinking about buying stock in indie Semiconductor, CohBar, Cellectar Biosciences, Lucira Health, or Dare Bioscience?
NEW YORK, July 12, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for INDI, CWBR, CLRB, LHDX, and DARE.
Jul 12, 2021 05:45 am ET
Daré Announces Collaborative Research Agreement (CRADA) for the Pivotal Phase 3 Study of Ovaprene®, an Investigational Hormone-Free Monthly Contraceptive
Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced that it entered into a Cooperative Research and Development Agreement (CRADA) with the Eunice Kennedy Shriver National Institute of Child Health and Human...
Jul 09, 2021 10:45 am ET
Thinking about buying stock in Dare Bioscience, Newegg, Zynga, 9 Meters Biopharma, or Kohl's?
NEW YORK, July 9, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DARE, NEGG, ZNGA, NMTR, and KSS.
Jul 08, 2021 10:45 am ET
Thinking about buying stock in ContextLogic, Dare Bioscience, 360 DigiTech, TAL Education, or Li Auto?
NEW YORK, July 8, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for WISH, DARE, QFIN, TAL, and LI.
Jul 07, 2021 08:30 am ET
Thinking about buying stock in OncoSec Medical, Dare Bioscience, Jaguar Health, Americas Gold and Silver, or Seelos Therapeutics?
NEW YORK, July 7, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ONCS, DARE, JAGX, USAS, and SEEL.
Jun 30, 2021 09:31 am ET
Thinking about buying stock in Dare Bioscience, Powerbridge Technologies, Atea Pharmaceuticals, Ammo Inc, or Eloxx Pharmaceuticals?
NEW YORK, June 30, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DARE, PBTS, AVIR, POWW, and ELOX.
Jun 28, 2021 08:00 am ET
Daré Bioscience Announces Positive Phase 1 Results for DARE-HRT1
Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced positive topline results from its Phase 1 clinical trial of DARE-HRT1. DARE-HRT1 is a novel IVR designed to deliver bio-identical 17β-estradiol and...
Jun 23, 2021 08:30 am ET
Thinking about buying stock in ConforMIS, Citius Pharmaceuticals, Clover Health, Capricor Therapeutics, or Dare Bioscience?
NEW YORK, June 23, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CFMS, CTXR, CLOV, CAPR, and DARE.
Jun 04, 2021 08:00 am ET
Daré Bioscience to Present at 2021 BIO Digital
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it has been selected to deliver a company presentation at 2021 BIO Digital, being held virtually June 10-11 and 14-18, 2021. Sabrina Martucci...
May 13, 2021 08:00 am ET
Daré Bioscience Reports First Quarter 2021 Financial Results and Provides a Company Update
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reported financial results for the quarter ended March 31, 2021 and provided a company update. “The strong momentum of 2020 continued during the first quarter of...
May 06, 2021 08:00 am ET
Daré Bioscience to Host First Quarter 2021 Financial Results and Company Update Conference Call and Webcast on May 13, 2021
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, May 13, 2021, to review its financial results for the quarter...
Apr 27, 2021 08:00 am ET
Daré Bioscience Announces Ovaprene®, a Novel Investigational Hormone-Free Contraceptive, Poster Presentation at the 2021 Annual Clinical and Scientific Meeting of the American College of Obstetricians
Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced that data from the Company’s postcoital test (PCT) clinical study of its novel investigational hormone-free monthly intravaginal contraceptive, Ovaprene,...
Apr 26, 2021 08:00 am ET
Daré Bioscience Announces the Presentation of DARE-BVFREE Phase 3 Clinical Trial Results at the 2021 Annual Clinical and Scientific Meeting of the American College of Obstetricians and Gynecologists
Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced that data from the DARE-BVFREE Phase 3 study of DARE-BV1, a thermosetting vaginal gel for the treatment of bacterial vaginosis, will be presented at the...
Apr 19, 2021 08:00 am ET
Daré Bioscience Appoints Dr. Sophia N. Ononye-Onyia to its Board of Directors
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced the appointment of Sophia N. Ononye-Onyia, PhD MPH MBA to its Board of Directors. “We are thrilled to add Dr. Ononye-Onyia to the Daré Board,” said...
Mar 30, 2021 08:00 am ET
Daré Bioscience Reports Full Year 2020 Financial Results and Provides a Company Update
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reported financial results for the year ended December 31, 2020 and provided a company update. “Despite the unique challenges posed during 2020, we achieved two...
Mar 24, 2021 08:00 am ET
Daré Bioscience Announces Initiation of Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder
Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, and Strategic Science & Technologies, LLC (SST), a Cambridge, MA based novel topical drug delivery company, today announced the initiation of the Phase 2b RESPOND clinical...
Mar 23, 2021 08:00 am ET
Daré Bioscience to Host Full Year 2020 Financial Results and Company Update Conference Call and Webcast on March 30, 2021
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Tuesday, March 30, 2021, to review its financial results for the year...
Mar 22, 2021 08:00 am ET
Daré Bioscience Completes Recruitment in Phase 1 Clinical Trial of DARE-HRT1, a Novel Intravaginal Ring Designed to Deliver Non-Oral, Bio-identical Hormone Therapy for the Treatment of Vasomotor Sympt
Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced completion of patient recruitment in its Phase 1 clinical trial of DARE-HRT1 being conducted through its wholly owned subsidiary in Australia. DARE-HRT1 is...
Mar 10, 2021 08:00 am ET
Daré Bioscience to Participate in Upcoming Virtual Conferences
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, its President and Chief Executive Officer, will participate in the following upcoming virtual conferences: M Vest and Maxim...
Mar 08, 2021 08:00 am ET
Daré Bioscience to Participate at the 33rd Annual Roth Conference
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, its President and Chief Executive Officer, will participate in a panel discussion titled “Women’s Health Companies Blazing...
Mar 02, 2021 08:00 am ET
Daré Bioscience to Present at the H.C. Wainwright Global Life Sciences Conference
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, its President and Chief Executive Officer, will present at the H.C. Wainwright Global Life Sciences Conference that will...
Feb 25, 2021 08:00 am ET
Daré Bioscience to Participate in Maxim Group’s Late Stage Innovations in Women’s Health Virtual Event
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, its President and Chief Executive Officer, will participate in a panel discussion for Maxim Group LLC’s Late Stage...
Feb 16, 2021 08:00 am ET
Daré Bioscience to Participate at the Women’s Health Innovation Series: Contraception Innovation Summit to be held Virtually on February 23, 2021
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, its President and Chief Executive Officer, will participate in a live panel discussion titled, The Evolution of Birth...
Feb 09, 2021 08:00 am ET
Daré Bioscience to Present at the 2021 BIO CEO & Investor Digital Conference
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, its President and Chief Executive Officer, will present at the BIO CEO & Investor Digital Conference that will take place...
Jan 20, 2021 07:31 am ET
Thinking about buying stock in Dare Bioscience, Endra Life Sciences, Lineage Cell Therapeutics, Inuvo Inc, or eMagin Corp?
NEW YORK, Jan. 20, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DARE, NDRA, LCTX, INUV, and EMAN.
Jan 05, 2021 08:00 am ET
Daré Bioscience to Participate in Fireside Chat at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, its President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright BIOCONNECT...
Dec 07, 2020 08:00 am ET
Daré Bioscience Announces Positive Topline Results From DARE-BVFREE, a Phase 3 Trial of DARE-BV1 in Patients Diagnosed with Bacterial Vaginosis
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced positive topline results from the DARE-BVFREE Phase 3 randomized, double-blinded, placebo-controlled clinical trial evaluating DARE-BV1 in 307 women...
Nov 12, 2020 08:00 am ET
Daré Bioscience Reports Third Quarter 2020 Financial Results and Provides Company Update
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reported financial results for the third quarter ended September 30, 2020 and provided a company update. “We made great progress toward our strategic and...
Nov 05, 2020 08:00 am ET
Daré Bioscience to Host Third Quarter 2020 Financial Results and Company Update Conference Call and Webcast on November 12, 2020
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, November 12, 2020, to review its financial results for the...
Oct 07, 2020 08:00 am ET
Daré Bioscience to Present at the 2020 BIO Investor Forum Digital
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, President and Chief Executive Officer, will present at the 2020 BIO Investor Forum, which will be held in a digital format...
Sep 21, 2020 08:00 am ET
Daré Bioscience Receives $0.9 million Under the Current Grant Supplement Award for Continued Development of its User-Controlled, Long Acting Reversible Contraceptive (DARE-LARC1)
Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced that it received the final approximately $0.9 million in funding under the current grant from the Bill & Melinda Gates Foundation. The grant payment will...
Sep 08, 2020 08:00 am ET
Daré Bioscience Announces Participation in Two Upcoming Virtual Conferences
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, Daré’s President and CEO, will participate in two upcoming virtual conferences: Women’s Health Innovation Summit 2020 Ms....
Sep 01, 2020 08:04 am ET
Daré Bioscience and Avomeen Form Strategic Partnership to Accelerate the Development of Daré’s Novel Pipeline of Women’s Health Programs
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, and Avomeen, an accredited, independent contract research, development, and manufacturing organization specializing in chemical analysis and product development, today...
Aug 20, 2020 08:00 am ET
Daré Bioscience Announces Publication of DARE-BV1 Proof of Concept Study for the Treatment of Bacterial Vaginosis
Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced the publication of a proof of concept study of DARE-BV1 in Clinical and Experimental Obstetrics & Gynecology, an international journal focused on...
Aug 19, 2020 08:00 am ET
Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to Support DARE-FRT1
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it received a Notice of Award of a grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), a division...
Aug 12, 2020 08:00 am ET
Daré Bioscience Reports Second Quarter 2020 Financial Results and Provides Company Update
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reported financial results for the second quarter ended June 30, 2020 and provided a company update. “During the second quarter, we continued to execute on key...
Aug 06, 2020 08:00 am ET
Daré Bioscience CEO to Participate in Maxim Group’s Leading Innovators in Women’s Health Virtual Conference
Daré Bioscience, Inc.(NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, President and Chief Executive Officer, will participate in a panel discussion during Maxim Group’s M-Vest Virtual Conference...
Aug 05, 2020 08:00 am ET
Daré Bioscience to Host Second Quarter 2020 Financial Results and Company Update Conference Call and Webcast on August 12, 2020
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Wednesday, August 12, 2020, to review its financial results for the...
Jul 27, 2020 08:00 am ET
Daré Bioscience Announces Initiation of Phase 1 Clinical Trial of DARE-HRT1, a Novel Intravaginal Ring Designed to Deliver Non-oral, Bio-identical Hormone Therapy for the Treatment of Menopausal Sympt
Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced the initiation of a Phase 1 clinical trial of DARE-HRT1. DARE-HRT1 is designed to deliver bio-identical 17β-estradiol and bio-identical progesterone...
Jun 24, 2020 08:00 am ET
Daré Bioscience Announces Publication of a Peer-Reviewed Journal Article Supporting the Use of the Postcoital Test Study as a Predictor of Contraceptive Effectiveness by Biology of Reproduction
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced the publication of a literature review article by Biology of Reproduction that identifies and reviews 10 postcoital test (PCT) studies of vaginal...
Jun 17, 2020 08:00 am ET
Daré Bioscience Announces Initiation of Pivotal Phase 3 Study of DARE-BV1 in Patients with Bacterial Vaginosis
Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced the initiation of the DARE-BVFREE study, a multi-center, double-blind, placebo-controlled Phase 3 clinical study of DARE-BV1 for the treatment of bacterial...
Jun 15, 2020 08:00 am ET
Daré Bioscience Announces Receipt of $1.5 Million Under the Current Grant Supplement Award for Continued Development of User-Controlled Long Acting Reversible Contraceptive
Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced the receipt by its wholly owned subsidiary of $1.5 million in additional grant funding from the Bill & Melinda Gates Foundation. The grant supports ongoing...
Jun 04, 2020 08:00 am ET
Daré Bioscience Announces Participation in BIO Digital 2020
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that the company will participate in the BIO International Convention, which will be held in a new, virtual event format for 2020, known as BIO Digital,...
May 14, 2020 08:00 am ET
Daré Bioscience Reports First Quarter 2020 Financial Results and Provides Company Update
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reported financial results for the first quarter ended March 31, 2020 and provided a company update. “The first quarter was an active one for Daré, beginning with...
May 11, 2020 08:00 am ET
Daré Bioscience and Health Decisions Form Strategic Partnership to Accelerate the Development of Daré’s Novel Pipeline of Women’s Health Programs
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, and Health Decisions, Inc., a full-service contract research organization (CRO) specializing in women’s health clinical research and diagnostic development, today...
May 07, 2020 08:00 am ET
Daré Bioscience to Host First Quarter 2020 Financial Results and Company Update Conference Call and Webcast on May 14, 2020
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, May 14, 2020, to review its financial results for the quarter...
Apr 28, 2020 08:00 am ET
Daré Bioscience CEO to Participate in Maxim Group’s Infectious Disease Virtual Conference
Daré Bioscience, Inc.(NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, President and Chief Executive Officer, will participate in a panel discussion during the Infectious Disease Virtual...
Apr 23, 2020 08:00 am ET
Daré Bioscience Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital Fund, LLC
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced it entered into a $15 million common stock purchase agreement and registration rights agreement with Lincoln Park Capital Fund, LLC (“LPC”), a...
Apr 01, 2020 08:00 am ET
Daré Bioscience Receives Third Notice of Award from National Institutes of Health Eunice Kennedy Shriver National Institute of Child Health and Human Development for the Development of Ovaprene®
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced it received a Notice of Award of $730,722 in a grant supporting the Ovaprene® postcoital test (PCT) clinical study research from the Eunice Kennedy Shriver...
Mar 30, 2020 08:00 am ET
Daré Bioscience Reports 2019 Financial Results and Provides a Company Update
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reported financial results for the year ended December 31, 2019 and provided a company update. “During the fourth quarter of 2019 and into early 2020, we made...
Mar 24, 2020 08:00 am ET
Daré Bioscience to Host Fourth Quarter and Full-year 2019 Financial Results and Company Update Conference Call and Webcast on March 30, 2020
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on March 30, 2020, to review its financial results for the fourth quarter...
Mar 10, 2020 08:00 am ET
Daré Bioscience Receives FDA Fast Track Designation for DARE-BV1 for the Treatment of Bacterial Vaginosis
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for DARE-BV1 for the treatment of bacterial vaginosis (BV) in women....
Mar 09, 2020 08:00 am ET
Daré Bioscience Presents Positive Sildenafil Cream, 3.6% Data Supporting Further Development for the Treatment of Female Sexual Arousal Disorder
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced the presentation of positive findings from a previously reported investigational study that used thermography technology to assess the pharmacodynamics of...
Feb 27, 2020 08:00 am ET
Daré Bioscience to Present at the Cowen 40th Annual Health Care Conference
Daré Bioscience, Inc.(NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, President and Chief Executive Officer, will present at the Cowen 40th Annual Health Care Conference on Wednesday, March 4,...
Feb 12, 2020 04:05 pm ET
Anika Therapeutics Names Board Member Dr. Cheryl Blanchard as Interim CEO
Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that Dr. Cheryl Blanchard, a member of the Company’s Board of Directors since August 2018, has been named interim Chief Executive Officer, effective immediately, while the Board continues its...
Feb 06, 2020 08:00 am ET
Daré Bioscience Regains Compliance with Nasdaq Minimum Equity Rule and Secures Capital to Advance Product Candidates
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, announced that it has been notified by The Nasdaq Stock Market LLC that the Company has regained compliance with the minimum stockholders’ equity requirement set forth in...
Feb 05, 2020 08:00 am ET
Daré Bioscience to Present at the 2020 BIO CEO & Investor Conference
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, its President and Chief Executive Officer, will present at the BIO CEO & Investor Conference on Tuesday, February 11, 2020,...
Jan 30, 2020 08:00 am ET
Daré Bioscience Regains Compliance with Nasdaq Minimum Bid Price Rule
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, announced that it was notified by the Nasdaq Office of General Counsel that the Company regained compliance with the minimum bid price rule in Nasdaq Listing Rule...
Jan 15, 2020 08:00 am ET
Daré Bioscience Schedules Conference Call for January 22, 2020 to Discuss Ovaprene® Licensing Agreement and General Corporate Update
Daré Bioscience, Inc.(NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Wednesday, January 22, 2020, to discuss the recently announced licensing...
Jan 13, 2020 07:00 am ET
 Bayer and Daré Bioscience Announce Exclusive Licensing Agreement for U.S. Commercial Rights to Ovaprene ®, an Investigational Hormone-Free, Monthly Contraceptive
Bayer, a leader in women’s health, and Daré Bioscience, Inc. (NASDAQ:DARE), a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women’s health, announced today that the companies have signed a license agreement under which Bayer may commercialize Daré’s investigational contraceptive product, Ovaprene® in the United States once approved by the FDA.
Dec 18, 2019 08:00 am ET
Daré Bioscience Announces FDA Clearance of IND Application for DARE-BV1 for Bacterial Vaginosis to Commence Pivotal Phase 3 Clinical Study
Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for DARE-BV1, its novel thermosetting...
Dec 11, 2019 08:00 am ET
Daré Bioscience Announces Alignment with the FDA on Phase 2b Study Design and Novel Primary Endpoint PRO Instruments to Support the Continued Clinical Development of Sildenafil Cream, 3.6%, a Potentia
Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, and Strategic Science & Technologies, LLC (SST), a Cambridge, MA based novel topical drug delivery company, today announced the outcome of a Type C meeting with the U.S....
Dec 10, 2019 08:00 am ET
Daré Bioscience Announces Feature Presentation at the15th US-Japan Symposium on Drug Delivery Systems
Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced that it will give one of the feature presentations at the 15th US-Japan Symposium on Drug Delivery Systems taking place Saturday, December 14 through...
Nov 21, 2019 08:00 am ET
Daré Bioscience Closes Previously Announced Acquisition of Microchips Biotech with a First-in-Class Wireless, User-Controlled Drug Delivery Platform
Daré Bioscience, Inc. (NASDAQ:DARÉ), a leader in women’s health innovation, today announced the closing of the previously announced acquisition by merger of privately-held Microchips Biotech, Inc.  As a result of the transaction, Microchips is a...
Nov 14, 2019 08:00 am ET
Daré Bioscience Reports Third Quarter 2019 Financial Results and Provides Company Update
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reported financial results for the quarter ended September 30, 2019 and provided a company update. “The third quarter was marked by tremendous progress for Daré...
Nov 12, 2019 08:00 am ET
Daré Bioscience Announces Positive Findings from a Postcoital Test Clinical Study of Ovaprene® Hormone-Free Contraceptive Candidate
Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced positive topline results from the Ovaprene postcoital test (PCT) clinical study, a multi-center, open-label, non-significant risk device pre-pivotal trial....
Nov 11, 2019 08:00 am ET
Daré Bioscience Enters into Agreement to Acquire Microchips Biotech Including Its First-in-Class Wireless, User-Controlled Drug Delivery Platform
Daré Bioscience, Inc. (NASDAQ:DARÉ), a leader in women’s health innovation, today announced it entered into an agreement to acquire privately-held Microchips Biotech, Inc.  Daré entered into the agreement to secure Microchips’ innovative, drug...
Nov 07, 2019 08:30 am ET
Daré Bioscience to Host Third Quarter 2019 Financial Results and Company Update Conference Call and Webcast
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, November 14, 2019, to review the Company's financial results...
Oct 31, 2019 08:00 am ET
Daré Bioscience Announces Presentation of Two Posters at American Association of Pharmaceutical Scientists 2019 PharmSci 360
Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced that it will be presenting findings from two nonclinical studies at the upcoming American Association of Pharmaceutical Scientists 2019 PharmSci 360...
Oct 28, 2019 08:00 am ET
Daré Bioscience and Strategic Science & Technologies Announce Presentation of Positive Findings from Thermography Clinical Study of Sildenafil Cream, 3.6 % in Healthy Women at the Sexual Medicine Soci
Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, and Strategic Science & Technologies, LLC (SST), a Cambridge, MA based novel topical drug delivery company, today announced a poster presentation at the Sexual Medicine...
Oct 14, 2019 08:00 am ET
Daré Bioscience to Participate in Two Upcoming Investor Conferences
Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced that Sabrina Johnson, its President and Chief Executive Officer, will present at two upcoming investor conferences: The 2019 Bio Investor Forum at the...
Oct 10, 2019 08:00 am ET
Daré Bioscience Announces a Poster Presentation on a Pharmacokinetic Study of DARE-FRT1, in Development for Sustained-Release Progesterone Therapy for Pregnancy Maintenance, at the American Society fo
Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced a poster presentation at the American Society for Reproductive Medicine (ASRM) 2019 Scientific Congress & Expo, which will take place in Philadelphia,...
Oct 07, 2019 08:00 am ET
Daré Bioscience to Present an Overview on its Intravaginal Ring (IVR) Technology in Development for Sustained-Release Hormone Therapy and Pregnancy Maintenance at the 9th Annual Partnership Opportunit
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that David Friend, Ph.D., its Chief Scientific Officer, will present at the 9th annual Partnership Opportunities in Drug Delivery conference being held...
Sep 11, 2019 08:00 am ET
Daré Bioscience Announces the Publication of a Pharmacokinetics Study of DARE-VVA1, a Novel Application of Tamoxifen for the Treatment of Vulvar and Vaginal Atrophy, in the International Journal of Ph
Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced the article entitled “Vaginal tamoxifen for treatment of vulvar and vaginal atrophy: Pharmacokinetics and local tolerance in a rabbit model over 28 days”...
Sep 09, 2019 08:00 am ET
Daré Bioscience Announces Completion of its Content Validity Study to Support the Continued Clinical Development of Sildenafil Cream, 3.6%, a Potential Therapy for Female Sexual Arousal Disorder
Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, and Strategic Science & Technologies, LLC (SST), a Cambridge, MA based novel topical drug delivery company, today announced the completion of a content validity study, a...
Sep 04, 2019 08:00 am ET
Daré Bioscience to Present at the H.C. Wainwright 21st Annual Global Investment Conference
Daré Bioscience, Inc.(NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, President and Chief Executive Officer, will present at the H.C. Wainwright 21st Annual Global Investment Conference being...
Aug 14, 2019 04:01 pm ET
Daré Bioscience Reports Second Quarter 2019 Financial Results and Company Update
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reported financial results for the second quarter ended June 30, 2019 and provided a Company update. “Daré made tremendous progress during the second quarter and...
Aug 12, 2019 08:00 am ET
Daré Bioscience Receives QIDP Designation from the FDA for DARE-BV1 for the Treatment of Bacterial Vaginosis
Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced that DARE-BV1, a novel thermosetting hydrogel containing clindamycin phosphate 2%, has been granted Qualified Infectious Disease Product (QIDP) designation...
Aug 08, 2019 08:00 am ET
Daré Announces Presentation of Positive Clinical Findings for Vaginal Administration of Novel Formulation of Clindamycin Phosphate for the Treatment of Bacterial Vaginosis at the 2019 Annual Meeting o
Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced the presentation of a poster at the upcoming annual meeting of the Infectious Diseases Society for Obstetrics and Gynecology taking place August 8-10, 2019...
Aug 06, 2019 08:00 am ET
Daré Bioscience to Host Second Quarter 2019 Financial Results and Company Update Conference Call and Webcast
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Wednesday, August 14, 2019, to review the Company's financial results for...
Jul 22, 2019 08:00 am ET
Daré Announces Presentation of Two Posters at the 2019 Controlled Release Society Annual Meeting & Exposition
Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced that it will be presenting two posters at the 2019 Controlled Release Society Annual Meeting & Exposition taking place in Valencia Spain, July 21st-24th....
Jul 17, 2019 08:00 am ET
Daré Bioscience Announces 2019 AAPS Best Abstract Award for Vaginal Tamoxifen for Treatment of Vulvovaginal Atrophy: Pharmacokinetics and Safety in a Rabbit Model
Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced that it has received notification from the American Association of Pharmaceutical Scientists (AAPS) of a Best Abstract Award for the abstract titled,...
Jul 15, 2019 08:00 am ET
Daré Bioscience Announces Appointment of Dr. William H. Rastetter as Chairman of the Board of Directors
Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, announced today that William H. Rastetter, Ph.D., a current member of its Board of Directors, was appointed Chairman of its Board of Directors effective July 11, 2019. “We...
Jun 26, 2019 08:00 am ET
Daré Bioscience Completes Recruitment in Pre-Pivotal Trial Of Monthly Woman-Controlled, Hormone-Free Contraceptive Candidate, Ovaprene®
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced completion of patient recruitment in its pre-pivotal, postcoital test (PCT) trial of Ovaprene®. Ovaprene is a self-administered, hormone-free, novel...
Jun 17, 2019 08:00 am ET
Daré Bioscience, Inc. Announces Positive Results in Thermography Feasibility Study with Sildenafil Cream, 3.6%, a Potential Therapy for Female Sexual Arousal Disorder
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced positive findings from an investigational study designed to evaluate the feasibility of using thermography technology to assess the pharmacodynamics of...
May 29, 2019 08:00 am ET
Daré Bioscience to Present at the 2019 BIO International Convention
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Johnson, President and Chief Executive Officer, will present at the 2019 BIO International Convention on Tuesday, June 4, 2019, starting at...
May 14, 2019 04:00 pm ET
Daré Bioscience Reports First Quarter 2019 Financial Results and Company Update
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reported financial results for the first quarter ended March 31, 2019 and provided a Company update. “The first quarter was an active one for Daré and positioned us...
May 08, 2019 08:00 am ET
Daré Bioscience Announces the Publication of a Pharmacokinetics Study of DARE-FRT1, a Potential Therapy for Preterm Birth and Fertility, in Drug Delivery and Translational Research
Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced the article entitled “Pharmacokinetics and tolerability of a novel progesterone intravaginal ring in sheep” was published online in the journal Drug...
May 07, 2019 08:00 am ET
Daré Bioscience to Host First Quarter 2019 Financial Results and Company Update Conference Call and Webcast
Daré Bioscience, Inc.(NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Tuesday, May 14, 2019, to review the Company's financial results for the...
Apr 15, 2019 08:00 am ET
Dr. James Simon, Award-Winning Physician, Presents on Ovaprene® as a Promising Novel Non-Hormonal Contraceptive Method in Clinical Development
Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced Ovaprene’s inclusion in a presentation to physicians on the latest forms of novel contraception. Ovaprene is Daré’s clinical stage, non-hormonal vaginal...
Apr 09, 2019 08:45 am ET
Daré Bioscience, Inc. Prices Underwritten Public Offering of Common Stock
Daré Bioscience, Inc. (NASDAQ:DARE), today announced the pricing of an underwritten public offering of 4,575,000 shares of its common stock at a price of $1.10 per share. The company has also granted to the underwriters a 30-day option to acquire...
Apr 08, 2019 04:28 pm ET
Daré Bioscience, Inc. Announces Proposed Public Offering of Common Stock
Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women’s health innovation, today announced that it intends to offer shares of its common stock in an underwritten public offering.  Daré expects to grant to the underwriters of the offering a 30-day...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.